tbuckley/cabot-search huggingface dataset:
Syndecan-2 enriches for hematopoietic stem cells and regulates stem cell repopulating capacity
Authors: Christina M. Termini, Amara Pang, Michelle Li, Tiancheng Fang, Vivian Y. Chang, John P. Chute
Journal: Blood (2021)

The discovery of novel hematopoietic stem cell (HSC) surface markers can enhance understanding of HSC identity and function. We have discovered a population of primitive bone marrow (BM) HSCs distinguished by their expression of the heparan sulfate proteoglycan Syndecan-2, which serves as both a marker and a regulator of HSC function. Syndecan-2 expression was increased 10-fold in CD150+CD48-CD34-c-Kit+Sca-1+Lineage- cells (long-term HSCs [LT-HSCs]) compared with differentiated hematopoietic cells. Isolation of BM cells based solely on syndecan-2 surface expression produced a 24-fold enrichment for LT-HSCs and sixfold enrichment for α-catulin+c-kit+ HSCs, and yielded HSCs with superior in vivo repopulating capacity compared with CD150+ cells. Competitive repopulation assays revealed the HSC frequency to be 17-fold higher in syndecan-2+CD34-KSL cells compared with syndecan-2-CD34-KSL cells and indistinguishable from CD150+CD34-KSL cells. Syndecan-2 expression also identified nearly all repopulating HSCs within the CD150+CD34-KSL population. Mechanistically, syndecan-2 regulates HSC repopulating capacity through control of expression of Cdkn1c (p57) and HSC quiescence. Loss of syndecan-2 expression caused increased HSC cell cycle entry, downregulation of Cdkn1c, and loss of HSC long-term repopulating capacity. Syndecan-2 is a novel marker of HSCs that regulates HSC repopulating capacity via control of HSC quiescence.
Thinking time, the scarce rocket fuel of health services
Authors: Kamran Abbasi
Journal: BMJ (2021)

The psychologist Edward de Bono, who died earlier this year, popularised lateral thinking (doi:10.1136/bmj.n1831).1 An IBM researcher told de Bono that his book Six Thinking Hats reduced meeting times to a quarter of what they had been. Creative thinking, argued de Bono, “is a skill that can be practised and nurtured.” That may be so, but thinking through innovative solutions and strategies requires time—and time is a commodity currently in short supply.

Without time to think, it’s hard to see our way out of the backlogs in cancer services that will take a decade to clear (doi:10.1136/bmj.n2352)2; or an end to overprescribing that results in 10% of prescriptions being inappropriate (doi:10.1136/bmj.n2338) …
747P Real-world experience of rucaparib in patients with ovarian cancer: A multicentre United Kingdom study
Authors: M. Lythgoe, S. Cleary, F. Kalofonou, T. Grunewald, R. Miller, D. Cartwright, R.M. Glasspool, R. Jones, S. Rossides, R. Ratnakumaran, A. Michael, I. McNeish, L. Tookman, J. Krell
Journal: Annals of Oncology (2021)
Outpatient Management of Heart Failure During the COVID-19 Pandemic After Adoption of a Telehealth Model
Authors: Yasser Sammour, John A. Spertus, Bethany A. Austin, Anthony Magalski, Sanjaya K. Gupta, Islam Shatla, Evelyn Dean, Kevin F. Kennedy, Philip G. Jones, Michael E. Nassif, Michael L. Main, Brett W. Sperry
Journal: JACC Heart Failure (2021)
1690P A multicenter randomized phase II open label study to compare the safety and efficacy of direct oral anticoagulants versus subcutaneous dalteparin for cancer-associated venous thromboembolism in patients with advanced upper gastrointestinal, hepatobiliary and pancreatic cancer
Authors: J.H. Kim, C. Yoo, S. Seo, J.H. Jeong, B-Y. Ryoo, K-P. Kim, J.B. Lee, K-W. Lee, J-W. Kim, I-H. Kim, M. Kang, H. Ryu, J. Cheon, S.R. Park
Journal: Annals of Oncology (2021)
129P Integration of gene expression and tumor-infiltrating lymphocytes (TILs) to predict pCR after neoadjuvant chemotherapy and nivolumab for patients with luminal B-like breast cancer in the phase II GIADA trial
Authors: M.V. Dieci, G. Griguolo, G. Bisagni, A. Musolino, S. Spazzapan, G. Moretti, F. Schiavi, C. Pinato, G.M. Vernaci, T. Giarratano, L. Urso, A. Tosi, G. Magni, M. Lo Mele, G.L. De Salvo, A. Rosato, V. Guarneri, P.F. Conte
Journal: Annals of Oncology (2021)
620P MGC018, an anti-B7-H3 antibody-drug conjugate (ADC), in patients with advanced solid tumors: Preliminary results of phase I cohort expansion
Authors: E. Shenderov, G.H.G. Mallesara, P.J. Wysocki, W. Xu, R. Ramlau, A.J. Weickhardt, J. Zolnierek, A. Spira, A.M. Joshua, J. Powderly, E.S. Antonarakis, S. Jang, J. Aragon-Ching, J. Shen, C. Paller, N.J. Vogelzang, K. Leu, J. Cortés, C. Bohac, I. Lugowska
Journal: Annals of Oncology (2021)
1079P Comparison of effectiveness and safety of nivolumab monotherapy or in combination therapy with ipilimumab in therapy-naïve and pretreated patients with advanced melanoma within the German noninterventional study NICO
Authors: R. Gutzmer, T. Eigentler, P. Mohr, M. Weichenthal, P. Dücker, C. Gebhardt, D. Göppner, I. Grimmelmann, S. Haferkamp, K.C. Kähler, F. Meier, C. Pföhler, T. Sickmann, A. Sindrilaru, P. Terheyden, S. Ugurel, J. Ulrich, J. Utikal, C. Weishaupt, D. Schadendorf
Journal: Annals of Oncology (2021)
Effect of neoadjuvant chemotherapy on CXCR4 expression in human breast cancer
Authors: Neal Holm, Kerry Byrnes, Danny Bourgeois, Bradford Siegele, Jesse Tubbs, Ben Li, Quyen Chu
Journal: Cancer Research (2007)

3487  Introduction: The overexpression of chemokine receptor CXCR4 has been shown to play a pivotal role in breast cancer metastasis. In vitro and animal studies have demonstrated decreased cell migration and abrogation of metastatic disease when agents that specifically block CXCR4 are given. Its clinical significance, however, is still being elucidated. Studies have shown CXCR4 to be overexpressed in human breast cancer tissue versus benign breast tissue. In recent literature, CXCR4 overexpression has also been associated with lymph node metastasis. In this study, we examined the effect of neoadjuvant chemotherapy on CXCR4 overexpression in breast cancer patients.  Methods: A prospective database of 1202 breast cancer patients was culled for this study. Eleven patients were identified with both pre- and post-neoadjuvant chemotherapy tissue specimens in our tissue bank. The patients were all diagnosed with locally advanced breast cancer (Stage IIB - III), and were found to have no evidence of systemic metastasis on subsequent staging work-up. The standard neoadjuvant chemotherapy regimen was four cycles of adriamycin and cyclophosphamide. Ten patients underwent post-neoadjuvant modified radical mastectomy, and one underwent breast conservation therapy. All eleven patients had either complete or partial response to chemotherapy. CXCR4 overexpression was quantified by western blot analysis and reported as x-fold elevated compared to Hela cells. Statistical analysis included Wilcoxon Rank Sum, Chi Square, Kaplan-Meier survival analysis and log-rank test.  Results: The mean CXCR4 level was 8.8 ± 5 fold (mean ± standard deviation over benign controls). Neoadjuvant chemotherapy reduced the mean CXCR4 level to 3.2 ± 2.7 fold, resulting in a mean difference of 5.6 ± 4.0 (62% reduction) and a statistically significant reduction in CXCR4 levels (p=0.002 Wilcoxon Rank Sum Test). Both pre-neoadjuvant and post-neoadjuvant CXCR4 levels were found to have no statistically significant correlation to tumor size, nodal, HER2, ER, PR status, or pathological stage (Chi Square Analysis). A persistently elevated post-neoadjuvant chemotherapy CXCR4 level above the mean (3.2) was associated with an increased risk of cancer recurrence (p=0.041 Log-rank test).  Conclusions: Neoadjuvant chemotherapy significantly reduces levels of CXCR4 overexpression in breast cancer. Elevated post-neoadjuvant chemotherapy CXCR4 expression appears to predict cancer recurrence in breast cancer patients, but a larger patient sample is necessary for proper evaluation.
Psychometric validation and responder definition of the sleep disturbance numerical rating scale in moderate‐to‐severe atopic dermatitis*
Authors: J. Puelles, F. Fofana, D. Rodriguez, J.I. Silverberg, A. Wollenberg, C. Dias Barbosa, M. Vernon, R. Chavda, S. Gabriel, C. Piketty
Journal: British Journal of Dermatology (2021)

Sleep disturbance (SD) is an important part of the burden of atopic dermatitis (AD), but patient-reported outcomes that are easy to understand and interpret in the target population have been lacking. A daily, single-item, self-reported SD 11-point numerical rating scale (NRS) was recently developed to assess SD for patients with moderate-to-severe AD, but its psychometric properties have not yet been described.To assess the psychometric properties of the SD NRS in patients with moderate-to-severe AD.The psychometric properties of the SD NRS were assessed using data from a phase IIb clinical trial in 218 adults with moderate-to-severe AD.Test-retest reliability of the SD NRS was substantial to almost perfect (interclass correlation 0·66-1·00) in participants who had stable SD or stable pruritus scores over 1 week. Baseline correlations were moderate to large (r > 0·30) between SD NRS and pruritus or sleep loss scores, but were small (r = -0·11 to 0·17) between SD NRS and EQ-5D-3L index and visual analogue scores, Hospital Anxiety and Depression Scale, Scoring Atopic Dermatitis, and Investigator's Global Assessment. The SD NRS could discriminate groups of participants in the expected direction according to different quality-of-life scores but not according to different clinician-reported disease severity scores. SD NRS scores significantly decreased as sleep loss, itch and quality-of-life scores improved. Analysis of meaningful change suggested a 2-5-point improvement as the initial range of responder definition in the SD NRS score.The SD NRS is a reliable, valid and responsive measure of SD in adults with moderate-to-severe AD.
1728P Clinical practice audit on prescribing frequency of buccal midazolam in patients with high grade gliomas
Authors: A. Reilly, C. Quinn, M. Traynor, S. Devanney, J. O'Shea, P. O'Connor, C. Murphy, R. Keogh, R.T. O'Dwyer, P. Bredin, S. Hamilton, A. Murphy, L. Judge, J. Naidoo, C. Matassa, P. Morris, D. O'Doherty, O.S. Breathnach, T. Doyle, L. Grogan
Journal: Annals of Oncology (2021)
Association of Maternal Depressive Symptoms During the Perinatal Period With Oppositional Defiant Disorder in Children and Adolescents
Authors: Berihun Assefa Dachew, James G. Scott, Jon E. Heron, Getinet Ayano, Rosa Alati
Journal: JAMA Network Open (2021)

<h3>Importance</h3> An association between perinatal maternal depression and risk of oppositional defiant disorder (ODD) in offspring has not been established. Identifying early determinants of ODD can help inform preventative intervention efforts. <h3>Objective</h3> To investigate the association between maternal perinatal depressive symptoms and the risk of ODD in offspring aged 7 to 15 years. <h3>Design, Setting, and Participants</h3> This population-based longitudinal birth cohort study used data from the Avon Longitudinal Study of Parents and Children (ALSPAC), in Bristol, UK. All pregnant women residents in Avon, UK, with expected delivery dates from April 1, 1991, to December 31, 1992, were invited to participate in the study. The study cohort ranged from approximately 8000 (at 7 years of age) to 4000 (at 15 years of age) mother-offspring pairs. Data were analyzed from November 2020 to July 2021. <h3>Main Outcomes and Measures</h3> Maternal depressive symptoms were measured using the Edinburgh Postnatal Depression Scale (EPDS) antenatally at 18 and 32 weeks of gestation and postnatally at 8 weeks and 8 months. This study primarily used a cutoff score of 12 or more on the EPDS to identify mothers with symptoms of depression, and the continuous EPDS scores were used to confirm the results of the main analyses. Offspring ODD at 7, 10, 13, and 15 years of age were diagnosed using the parent-reported Development and Well-Being Assessment. <h3>Results</h3> Of 7994 mother-offspring pairs for whom data were available on offspring ODD at 7 years, 4102 offspring (51.3%) were boys. The mean (SD) age of mothers was 28.6 (4.6) years. Maternal antenatal depressive symptoms (measured at 32 weeks of gestation) were associated with offspring ODD (adjusted odds ratio [AOR], 1.75; 95% CI, 1.33-2.31). Offspring of mothers with postpartum depressive symptoms at 8 weeks and 8 months were more than 2 times more likely to have a diagnosis of ODD over time (AOR at 8 weeks, 2.24 [95% CI, 1.74-2.90]; AOR at 8 months, 2.04 [95% CI, 1.55-2.68]), and maternal persistent depressive symptoms were associated with a 4-fold increased risk of offspring ODD (AOR, 3.59; 95% CI, 1.98-6.52). <h3>Conclusions and Relevance</h3> These findings suggest that perinatal depressive symptoms are associated with ODD in offspring and further support the need for early identification and management of prenatal and postnatal depression in women of childbearing age.
21P Analysis of germline variants in the immune response-related genes in BRCA1 mutation carriers: Possible modifying effect on age-dependent BRCA1 penetrance
Authors: E.S. Kuligina, A.A. Romanko, E.N. Suspitsin, A.V. Tumakova, A.S. Martianov, I.V. Bizin, J. Gorgul, G.A. Yanus, A. Kashyap, C. Cybulski, A. Jakubowska, J. Lubiński, E.N. Imyanitov
Journal: Annals of Oncology (2021)
935P An exploratory subgroup analysis of a phase II/III trial of donafenib versus sorafenib in the first-line treatment of advanced hepatocellular carcinoma
Authors: F. Bi, S. Qin, S. Gu, Y. Bai, Z. Chen, Z. Wang, J. Ying, Y. Lu, Z. Meng, H. Pan, P. Yang, H. Zhang, X. Chen, A. Xu, L. Liu
Journal: Annals of Oncology (2021)
Factors Associated With Primary Nonresponsiveness to Antibiotics in Adults With Uncomplicated Acute Appendicitis
Authors: Jussi Haijanen, Suvi Sippola, Eliisa Löyttyniemi, Saija Hurme, Juha Grönroos, Tero Rautio, Paulina Salminen
Journal: JAMA Surgery (2021)

This secondary analysis of a randomized clinical trial assesses potential preintervention findings associated with primary nonresponsiveness to antibiotics in adults with uncomplicates acute appendicitis.
1835P Clinical outcome and prognostic factors for Asian patients in phase I clinical trials
Authors: J. Loh, J. Wu, J. Chieng, A. Chan, W-P. Yong, R. Sundar, S.C. Lee, A. Wong, J.S. Lim, D.S. Tan, R. Soo, W.J. Chng, B.C. Goh, B.C. Tai, C.E. Chee
Journal: Annals of Oncology (2021)
1519TiP Japanese Society of Medical Oncology/Health Authority of the Japanese Government Cooperative Virtual Educational Program for Improving the Clinical Annotation for Cancer Genomic Medicine
Authors: T. Amano, K. Sunami, Y. Naito, D. Ennishi, M. Imai, H. Kage, M. Kanai, H. Kenmotsu, K. Komine, T. Koyama, Maeda T., S. Morita, Y. Saigusa, D. Sakai, K. Ichiro, T. Kozuki, H. Sakashita, S. Kohsaka, K. Tsuchihara, T. Yoshino
Journal: Annals of Oncology (2021)
Skeletal muscle regeneration with robotic actuation–mediated clearance of neutrophils
Authors: Bo Ri Seo, Christopher J. Payne, Stephanie L. McNamara, Benjamin R. Freedman, Brian J. Kwee, Sungmin Nam, Irene de Lázaro, Max Darnell, Jonathan T. Alvarez, Maxence O. Dellacherie, Herman H. Vandenburgh, Conor J. Walsh, David J. Mooney
Journal: Science Translational Medicine (2021)

Mechanical stimulation (mechanotherapy) can promote skeletal muscle repair, but a lack of reproducible protocols and mechanistic understanding of the relation between mechanical cues and tissue regeneration limit progress in this field. To address these gaps, we developed a robotic device equipped with real-time force control and compatible with ultrasound imaging for tissue strain analysis. We investigated the hypothesis that specific mechanical loading improves tissue repair by modulating inflammatory responses that regulate skeletal muscle regeneration. We report that cyclic compressive loading within a specific range of forces substantially improves functional recovery of severely injured muscle in mice. This improvement is attributable in part to rapid clearance of neutrophil populations and neutrophil-mediated factors, which otherwise may impede myogenesis. Insights from this work will help advance therapeutic strategies for tissue regeneration broadly.
455P Concordance of baseline RAS mutational status (ms) between tissue and cell-free DNA (cfDNA) and association with overall response rate (ORR) in first-line (1L) metastatic colorectal cancer (mCRC) patients (pts): PERSEIDA study (cohort 2) (NCT02792478)
Authors: M. Valladares-Ayerbes, M.J. Safont, E. González-Flores, P. García-Alfonso, E. Aranda Aguilar, A.M. López Muñoz, L. Cirera Nogueras, E. Falco Ferrer, N. Rodriguez Salas, J. Aparicio, M. Llanos, O.A. Castillo Trujillo, P. Pimentel Cáceres, J.J. Cruz-Hernández, M. Salgado Fernández, A. Salud Salvia, R. Garcia-Carbonero, B. Massuti Sureda, M.A. Vicente Conesa, A. Lloansi Vila
Journal: Annals of Oncology (2021)
142P Long-term follow-up of neoadjuvant dual anti-HER2 therapy with trastuzumab and lapatinib plus paclitaxel, with or without endocrine therapy for HER2-positive primary breast cancer: Neo-LaTH (JBCRG-16) study
Authors: T. Fujisawa, N. Masuda, N. Yamamoto, H. Iwata, H. Bando, T. Aruga, E. Tokunaga, S. Ohtani, T. Takano, K. Inoue, N. Suganuma, M. Takada, K. Aogi, K. Sakurai, H. Shigematsu, K. Kuroi, H. Haga, S. Ohno, S. Morita, M. Toi
Journal: Annals of Oncology (2021)
608P Apalutamide (APA) efficacy and safety in Asian patients with metastatic castration-sensitive prostate cancer (mCSPC)
Authors: B.H. Chung, J. Huang, H. Uemura, Y.D. Choi, Z. Ye, H. Suzuki, T.W. Kang, D. He, J.Y. Joung, S.D. Brookman-May, S. McCarthy, A. Bhaumik, J. He, S.D. Mundle, S. Chowdhury, N. Agarwal, D. Ye, K.N. Chi, H. Uemura
Journal: Annals of Oncology (2021)
1385P Phase II study of neoadjuvant camrelizumab combined with chemoradiation for locally advanced proximal gastric cancer (Neo-PLANET, NCT03631615)
Authors: Z-Q. Tang, Y. Wang, D. Liu, Y-Y. Yu, Y-H. Cui, C. Tang, J. Sun, Q. Zhang, Y. Ji, G-F. Ma, Z-B. Shen, F-L. Liu, K-T. Shen, X. Wang, T-S. Liu, Y-H. Sun
Journal: Annals of Oncology (2021)
Not by signalling alone: Music's mosaicism undermines the search for a proper function
Authors: Anton Killin, Carl Brusse, Adrian Currie, Ronald J. Planer
Journal: Behavioral and Brain Sciences (2021)

Abstract Mehr et al. seek to explain music's evolution in terms of a unitary proper function – signalling cooperative intent – which they cash out in two guises, coalition signalling and (allo)parental attention signalling. Although we recognize the role signalling almost certainly played in the evolution of music, we reject “ultimate” causal explanations which focus on a unidirectional, narrow range of causal factors.
1315P Impact of high fasting plasma glucose in the clinical outcome of patients with advanced NSCLC with PD-L1 ≥ 50% treated with frontline pembrolizumab
Authors: S. Llop Serna, E. Puig, R. Palmero, J. Brenes, N. Vilariño, J.C.C. Ruffinelli, C. Mesia Barroso, J. Saldaña Cañada, M. Jove Casulleras, I. Brao Perez, M. Arellano, F.N. Luciano Mateo, I. Peiró Martínez, C. Muñoz Pinedo, E. Nadal
Journal: Annals of Oncology (2021)
WHO hails “historic day” as it recommends malaria vaccine
Authors: Jacqui Wise
Journal: BMJ (2021)

The World Health Organization has recommended widespread use of the RTS,S malaria vaccine among children in sub-Saharan Africa and other areas with moderate to high malaria transmission in a move that could save tens of thousands of young lives each year.

WHO’s director, Tedros Adhanom Ghebreyesus, who started his career as a malaria researcher, told a briefing in Geneva, “I longed for the day that we would have an effective vaccine against this ancient and terrible disease. Today is that day: an historic day.”

The recommendation comes after two independent advisory bodies—the Strategic Advisory Group of Experts on Immunization and the Malaria Policy Advisory Group—considered the available evidence, including results from an ongoing pilot programme in Ghana, Kenya, and Malawi that has reached more than 800 000 children since 2019.1

Trials reported in 2015 showed that the vaccine could prevent four in 10 cases of malaria and three in 10 severe cases. But there were doubts that …
1367TiP IMPRINTER: An open label, multi-center, dose escalation/expansion, phase I study of IMU-201 (PD1-Vaxx), a B-cell immunotherapy, in adults with non-small cell lung cancer
Authors: R. Laeufle, G. Richardson, J.J.W. Park, M. Gutierrez, M. Boyer, D. Carbone, P. Savvides, T. Bekaii-Saab, P. Kaumaya, T. Phan, N. Ede, L. Chong, B. Nixon, A. Good
Journal: Annals of Oncology (2021)
1390P Evaluation of event-free survival as a trial-level surrogate for overall survival for patients with gastric and gastroesophageal junction adenocarcinoma in neoadjuvant/adjuvant settings
Authors: J. Xie, A. Valderrama, L. Yin, S. Zhang, C-S. Shih, C. Gu, P. Bhagia, Z. Wainberg
Journal: Annals of Oncology (2021)
253P Risk factor (RF) identification (ID) and hyperglycemia (HG) prevention with alpelisib (ALP) + fulvestrant (FLV) in PIK3CA-mutated, hormone-receptor positive (HR+), human epidermal growth factor-2 negative (HER2-) advanced breast cancer (ABC)
Authors: S. Burnette, E. Poehlein, H-J. Lee, J. Force, K. Westbrook, H. Moore
Journal: Annals of Oncology (2021)
1447P Efficacy and toxicity profile of trans dermal buprenorphine for cancer pain management: Experience from a tertiary care center in northern India
Authors: V. Goel, N. Patnaik, V.P.B. Koyyala, V. Talwar, K. Chowdhary, P. Jain, P. Goyal, S. Raina
Journal: Annals of Oncology (2021)
576MO Health-related quality of life (HRQoL), pain and safety outcomes in the phase III VISION study of 177Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer
Authors: K. Fizazi, K. Herrmann, B.J. Krause, K. Rahbar, K.N. Chi, M.J. Morris, O. Sartor, S.T. Tagawa, A.T. Kendi, N.J. Vogelzang, J. Calais, J. Nagarajah, X.X. Wei, V.S. Koshkin, J-M. Beauregard, B. Chang, M. DeSilvio, R.A. Messmann, J. de Bono
Journal: Annals of Oncology (2021)
316P Attitudes towards the use of stereotactic body radiation therapy in oligometastatic breast cancer: Results of an OncoAlert survey
Authors: P. Vukovic, I. Meattini, M. Lambertini, E. de Azambuja, A. Prat, P.G. Aftimos, M. Lustberg, I. Kruljac, G. Morgan
Journal: Annals of Oncology (2021)
Abstract 11024: Serum Ceramide Ratios Predict Cardiovascular Events in Patients With Type 2 Diabetes Independently From the Presence of Coronary Artery Disease
Authors: Andreas Leiherer, Axel Muendlein, Christoph H Saely, Reijo Laaksonen, Mitja Lääperi, Alexander Vonbank, Arthur Mader, Peter Fraunberger, Heinz Drexel
Journal: Circulation (2019)

Introduction: The ceramide ratios Cer(d18:1/16:0)/Cer(d18:1/24:0), Cer(d18:1/18:0)/Cer(d18:1/24:0) and Cer(d18:1/24:1)/Cer(d18:1/24:0) have recently been reported to be associated with cardiovascul...
Overdiagnosis is increasing the carbon footprint of healthcare
Authors: Alexandra Barratt, Forbes McGain
Journal: BMJ (2021)

Overdiagnosis is increasing the carbon footprint of healthcare Tackling overdiagnosis takes on a new urgency in the context of a climate emergency Alexandra Barratt, 1 Forbes McGain 2Clinical practice varies-some is excellent, delivering high quality care, improving health outcomes, and representing excellent value for money.But research over the past two decades has established that a significant minority of clinical care is low value, wasteful, or harmful.
1610P Delivery of ONCOlogic care at HOME: Ready for “ONCOHOME”
Authors: M. Ratti, G. Procopio, V. Guadalupi, G. Grizzi, M. Bonomi, J. Saleri, A. Gobbi, R. Marchi, G. Pogliacomi, G. Donati, M. Nazzari, N. Bacciocchini, M. Brighenti, B. Perrucci, M.O. Giganti, S. Panni, M. Donini, A. Curti, V. Gregorc, R. Passalacqua
Journal: Annals of Oncology (2021)
1293P KN046 (an anti-PD-L1/CTLA-4 bispecific antibody) in combination with platinum doublet chemotherapy as first-line (1L) treatment in patients with advanced NSCLC harboring resistant oncogenic driver alterations
Authors: W. Fang, Y. Yang, Y. Huang, X. Li, S. Huang, J. Wu, Y. Li, B. Chang, S. Hu, S. Yang, J. Xu, H. Van, L. Zhi, Y. Xia, L. Li, F. Yang, Y. Xia, T. Xu, L. Zhang
Journal: Annals of Oncology (2021)